Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: Grand View Research | PRODUCT CODE: 1813955

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1813955

Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunosuppressive Drugs, Transplantation, Supportive Care), By End Use ( Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Amyloidosis Treatment Market Summary

The global amyloidosis treatment market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The industry is experiencing growth due to rising awareness of the disease, advancements in diagnostic methods, and an increasing number of patients being identified at earlier stages with accurate diagnoses.

Innovations such as advanced imaging, mass spectrometry, and genetic testing are allowing healthcare providers to better distinguish between amyloidosis subtypes, supporting more precise and effective treatment approaches. The establishment of specialized care centers and the availability of trained medical experts are further enhancing access to comprehensive care. Additionally, the growing incidence of age-related transthyretin amyloidosis, particularly among older populations, is driving demand for long-term therapeutic solutions. These factors are prompting pharmaceutical companies to expand their research pipelines, while the recognition of amyloidosis as a condition that can be effectively managed with timely treatment is transforming global patient care practices.

One of the key drivers fueling the amyloidosis treatment market is the regulatory advancement of gene-silencing therapies for transthyretin amyloidosis. For instance, in March 2025, the U.S. FDA approved Amvuttra (vutrisiran) as the first gene-silencing therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The approval was backed by Phase III HELIOS-B trial results showing a 28% reduction in all-cause mortality and cardiovascular events. Patients also experienced notable improvements in functional capacity and quality of life. This advancement offers a new treatment pathway directly reducing TTR protein production with only four annual injections. The approval is expected to boost early diagnosis, expand RNA-based therapy adoption, and intensify competition in the ATTR-CM market.

The regulatory approval of highly effective small-molecule stabilizers targeting transthyretin amyloidosis is a major development boosting the amyloidosis treatment market. For instance , in December 2024, the U.S. FDA approved Attruby (acoramidis), a near-complete transthyretin (TTR) stabilizer developed by BridgeBio Pharma, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) (BridgeBio). Acoramidis demonstrated over 90% stabilization of TTR and significantly reduced cardiovascular death and hospitalizations in the pivotal ATTRibute-CM trial. The approval introduces a convenient oral alternative that expands treatment options beyond RNAi-based therapies and meets the needs of a broader patient base. It is expected to intensify market competition and accelerate innovation in ATTR-CM therapeutics. With improved efficacy, tolerability, and ease of administration, acoramidis is positioned to reshape treatment paradigms for newly diagnosed and long-term ATTR-CM patients.

The projected surge in cancer cases, with the United States expected to see a 47.5% increase and Canada a 60.7% increase by 2050, the rising prevalence of chronic and complex diseases. This trend emphasizes the growing strain on healthcare systems, which in turn accelerates demand for advanced diagnostics and treatment solutions. Given that cancer and amyloidosis share overlapping clinical challenges such as organ dysfunction, protein misfolding, and systemic inflammation, the increase in cancer incidence indirectly raises awareness and identification of related conditions like amyloidosis. This linkage is likely to enhance patient screening, expand healthcare investments, and strengthen treatment infrastructure.

Consequently, the industry is expected to benefit from these dynamics as rising cancer prevalence fuels both clinical awareness and therapeutic innovation. With heightened demand for precision therapies, there will be an increased focus on monoclonal antibodies, targeted treatments, and supportive care solutions that address disease progression more effectively. Moreover, pharmaceutical companies and healthcare providers are likely to increase research funding and collaborations, leveraging advancements in oncology to accelerate drug development for amyloidosis. This synergy will position the amyloidosis market for significant growth in the coming decades.

Global Amyloidosis Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyloidosis treatment market report based on treatment, end-use, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Immunosuppressive Drugs
  • Transplantation
  • Supportive Care
  • Surgery
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-2-68038-443-7

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End-use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Amyloidosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Amyloidosis Treatment Market: Treatment Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2033
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 4.5. Immunosuppressive Drugs
    • 4.5.1. Immunosuppressive Drugs Market, 2021 - 2033 (USD Million)
  • 4.6. Transplantation
    • 4.6.1. Transplantation Market, 2021 - 2033 (USD Million)
  • 4.7. Supportive Care
    • 4.7.1. Supportive Care Market, 2021 - 2033 (USD Million)
  • 4.8. Surgery
    • 4.8.1. Surgery Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Amyloidosis Treatment Market: End Use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2033
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 5.5. Ambulatory Surgical Centers
    • 5.5.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
  • 5.6. Home Care Settings
    • 5.6.1. Home Care Settings Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Amyloidosis Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  • 6.4. North America
    • 6.4.1. North America Amyloidosis Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Amyloidosis Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Treatment Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Johnson & Johnson Services, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Treatment Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. GSK plc
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Treatment Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Takeda Pharmaceutical Company Limited
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Treatment Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Amgen Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Treatment Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Treatment Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Novartis AG
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Treatment Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. F. Hoffmann-La Roche Ltd
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Treatment Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Merck KGaA
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Treatment Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Treatment Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Alnylam Pharmaceuticals, Inc.
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Treatment Benchmarking
      • 7.5.11.4. Strategic Initiatives
Show more
Product Code: GVR-2-68038-443-7

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global amyloidosis treatment market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 5 Global amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 6 North America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 8 North America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 9 U.S. amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 U.S. amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 11 Canada amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 12 Canada amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 13 Mexico amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 14 Mexico amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 15 Europe amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 17 Europe amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 18 UK amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 UK amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 20 Germany amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 21 Germany amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 22 France amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 France amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 24 Italy amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 25 Italy amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 26 Spain amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 27 Spain amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 28 Norway amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Norway amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 30 Denmark amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 31 Denmark amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 32 Sweden amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 33 Sweden amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 37 Japan amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Japan amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 39 China amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 40 China amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 41 India amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 42 India amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 43 Australia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Australia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 45 South Korea amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 46 South Korea amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 47 Thailand amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 48 Thailand amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 49 Latin America amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Latin America amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 52 Brazil amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 53 Brazil amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 54 Argentina amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 55 Argentina amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Amyloidosis treatment market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 59 South Africa amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 South Africa amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 63 UAE amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 64 UAE amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)
  • Table 65 Kuwait amyloidosis treatment market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 Kuwait amyloidosis treatment market, by end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Amyloidosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and treatment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Amyloidosis treatment market dynamics
  • Fig. 12 Amyloidosis treatment market: Porter's five forces analysis
  • Fig. 13 Amyloidosis treatment market: PESTLE analysis
  • Fig. 14 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 15 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 16 Immunosuppressive drugs market, 2021 - 2033 (USD Million)
  • Fig. 17 Transplantation market, 2021 - 2033 (USD Million)
  • Fig. 18 Supportive care market, 2021 - 2033 (USD Million)
  • Fig. 19 Surgery market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 End use market, 2021 - 2033 (USD Million)
  • Fig. 22 Hospitals & clinics market, 2021 - 2033 (USD Million)
  • Fig. 23 Ambulatory surgical centers market, 2021 - 2033 (USD Million)
  • Fig. 24 Home care settings market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Amyloidosis treatment market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 52 Asia Pacific amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 70 MEA amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait amyloidosis treatment market, 2021 - 2033 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!